IPN:EPA
Ipsen SA
€166.40
arrow_downward
-0.36%(-0.60) 1D
Nov 13, 5:35:23 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPN...
Open
€167.40
High
€168.60
Low
€165.30
Mkt. cap
13.87B
Avg. vol.
114.56K
Volume
82.44K
P/E ratio
26.95
52-wk high
€174.00
52-wk low
€115.60
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
Open
€167.40
High
€168.60
Low
€165.30
Mkt. cap
13.87B
Avg. vol.
114.56K
Volume
82.44K
P/E ratio
26.95
52-wk high
€174.00
52-wk low
€115.60
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds
Nasdaq
·
1 day ago
Chartstopper: November 13, 2026
Bloomberg.com
·
19 hours ago
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Profile
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
About Ipsen SA
CEODavid Loew
Employees5.54K
Founded1929
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteipsen.com